Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Adalimumab plus methotrexate effective for long-standing rheumatoid arthritis

16.08.2005


For people with long-standing rheumatoid arthritis, combined treatment with the new “biologic” drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

In six randomized controlled trials, comprising 2381 people with at least 10 years of the disease, the authors report that adalimumab (Humira) plus methotrexate decreased pain and swelling in patients who fail to respond to standard treatment.

Adalimumab “is even more active when used combined with methotrexate,” according to lead reviewer Federico Navarro-Sarabia, M.D., chair of rheumatology at the Hospital Universitario Virgen Macarena in Seville, Spain, and colleagues. “More people had improved symptoms with adalimumab alone than with fake injections, but the improvement was not as much as when adalimumab was taken in combination with methotrexate.”



The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The reviewers found that after six months, 43 percent of all subjects on adalimumab plus methotrexate had achieved a 50-percent improvement in symptoms, compared with 9 percent of all subjects receiving placebo plus methotrexate.

In the longest-running study, X-rays showed that adalimumab injections slowed progression of joint damage more than placebo.

Adalimumab was given in injections of 40 milligrams every other week or 20 milligrams per week.

The reviewers determined clinical effectiveness of each drug by measuring patients’ improvement using a symptom scale devised by the American College of Rheumatology. They measured disease progression using European League Against Rheumatism radiologic criteria.

They found that the rate of side effects was not significantly different between the adalimumab and placebo groups, but noted that the long-term side effects of adalimumab treatment have not yet been determined.

Adalimumab works by preventing a protein called tumor necrosis factor (TNF) from signaling the release of joint-damaging substances. The other FDA-approved TNF blockers are etanercept (Enbrel) and infliximab (Remicade). Adalimumab is approved for the treatment of moderate to severe rheumatoid arthritis in adults who do not respond to other treatments.

Methotrexate is the most widely used of “disease modifying antirheumatic drugs” among rheumatoid arthritis patients. Although DMARDs play an important role in arthritis treatment, only one, leflunomide, was developed specifically for rheumatoid arthritis treatment. Methotrexate was developed as a cancer treatment.

“What we might be seeing here is a synergistic effect,” said Scott Zashin, M.D., coauthor of a book on TNF blockers for arthritis, and clinical assistant professor at the University of Texas-Southwestern Medical School in Dallas. “Doctors and patients need to know, and this review supports the claim, that combination therapy will generally have a more robust effect, though some patients will do well on either drug alone. For patients with long-standing disease, this review affirms combination therapy as the standard of care.”

Addressing future research priorities, the reviewers wrote, “The available clinical trials with adalimumab are short-term studies (six-months duration) and there is only one twelve-month study. Long-term efficacy and safety studies are needed.”

Rheumatoid arthritis is an autoimmune disease which develops when certain cells of the immune system malfunction and attack healthy joints. The cause of rheumatoid arthritis is unknown. The primary focus of the inflammation is in the synovium, the lining tissue of the joint. Inflammatory chemicals released by the immune cells cause swelling and damage to cartilage and bone.

More than 2 million Americans suffer from rheumatoid arthritis, according to the American College of Rheumatology. About 75 percent of those affected are women. While the disease appears most commonly between the ages of 40 and 60, it can develop at any age.

Navarro-Sarabia F, et al. Adalimumab for treating rheumatoid arthritis. The Cochrane Database of Systematic Reviews 2005, Issue 3.

Federico Navarro-Sarabia | EurekAlert!
Further information:
http://www.hbns.org
http://www.cfah.org

More articles from Studies and Analyses:

nachricht Amputees can learn to control a robotic arm with their minds
28.11.2017 | University of Chicago Medical Center

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Long-lived storage of a photonic qubit for worldwide teleportation

12.12.2017 | Physics and Astronomy

Multi-year submarine-canyon study challenges textbook theories about turbidity currents

12.12.2017 | Earth Sciences

Electromagnetic water cloak eliminates drag and wake

12.12.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>